People with Advanced Thyroid Cancer in Germany and Austria Now Able to Benefit from New Thyroid Cancer Treatment Lenvima

Publicado 01/07/2015 1:02:56CET

Two recent subanalyses from the SELECT study have been presented at the Endocrine Society Congress 2015 (ENDO). The first reports the results of the open-label extension phase of SELECT and aims to assess the crossover of patients in the placebo arm to the optional open-label lenvatinib treatment period. The results highlight that patients who crossed over from the placebo arm achieved a median PFS of 12.4 months with open-label lenvatinib treatment. Although toxicities were substantial, these were generally managed with medications, dose interruption, and dose reductions.[11]

The second abstract examines the relationship between thyroid abnormalities and their effect on the safety and efficacy outcomes in SELECT. The analysis shows that although an increase in thyroid-stimulating hormone (TSH) levels was a frequent complication, its direct relationship to lenvatinib therapy has not been established and there is no evidence TSH levels affect tumour responses to lenvatinib treatment.[12]

About Thyroid Cancer 

Thyroid cancer refers to cancer that forms in the tissues of the thyroid gland, located at the base of the throat near the trachea.[13] It is more common in women than in men and most are in their 40s or 50s at time of diagnosis.[14]

Thyroid cancer affects more than 52,000 people in Europe each year.[7] The incidence of thyroid cancer has increased significantly in the last decade by 69% and 65% in men and women, respectively.[15] The most common types of thyroid cancer, papillary and follicular (including Hurthle cell), are classified as differentiated thyroid cancer (DTC) and account for approximately 85-90% of all cases.[16],[17],[18] The remaining cases are classified as either medullary (3-4% of cases)[19] or anaplastic (1-2% of cases).[17],[18]

About Eisai Co., Ltd. 

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in multiple therapeutic areas with high unmet medical needs, including Oncology and Neurology. 

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit http://www.eisai.com.  

References  

1. European Commission Decision. Data on file. 2015

2. SPC Lenvima. Available at: http://www.medicines.org.uk/emc/medicine/30412 Accessed: June 2015

3. Schlumberger M et al. Lenvatinib versus placebo in radioiodine refractory differentiated thyroid cancer. NEJM 2015; 372: 621-630. Available at http://www.nejm.org/doi/full/10.1056/NEJMoa1406470  Accessed: June 2015

4. Matsui J, et al . Clin Cancer Res 2008;14:5459-65

5. Matsui J, et al . Int J Cancer 2008;122:664-671

6. Okamoto K, et al . Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. ACS Med. Chem. Lett 2015;6:89-94

7. EUCAN 2015.   http://eu-cancer.iarc.fr/EUCAN/Cancer.aspx?Cancer=35 [http://eu-cancer.iarc.fr/EUCAN/Cancer.aspx?Cancer=35 ] Accessed: June 2015

8. Kilfoy BA et al . Cancer Causes Control. 2009 Jul;20(5):525-31

9. Butterfly Thyroid Cancer Trust. About Thyroid Cancer. Available at : http://www.butterfly.org.uk/about.htm  Accessed: June 2015

10. Newbold K et al . Phase 3 study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT): Results and subgroup analysis of patients from Europe. Presented as a digital poster at ETA 2014.  

11. Robinson B et al . Open-Label Extension Phase Outcomes of the Phase 3 Select Trial of Lenvatinib in Patients with 131I-Refractory Differentiated Thyroid Cancer. ENDO 2015

12. Sherman S et al . Relationship Between Thyroid-Stimulating Hormone Levels and Outcomes from the Randomized, Double-Blind, Phase 3 Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid (SELECT). ENDO 2015

13. National Cancer Institute at the National Institute of Health. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/Pat...  Accessed: June 2015

14. Brito J et al . BMJ 2013; 347

15. Cancer Research UK. Thyroid cancer incidence statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/type...  Accessed: June 2015

16. Pacini F et al . ESMO Guidelines Working Group. Ann Oncol. 2012;23(suppl 7) :vii110-vii119

17. Thyroid Cancer Basics. 2011, 2012, at: http://www.thyca.org  Accessed: June 2015

18. Cooper DS et al ; Thyroid. 2009;19:1167-1214

19. National Cancer Institute. Medullary Thyroid Cancer. http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/Hea...  Accessed: June 2015

 

Date of preparation: June 2015   

Job code: Lenvima-UK0036 

CONTACT: Media Enquiries: Eisai: Cressida Robson / Ben Speller,+44-(0)7908-314-155 / +44-(0)7908-409416, Cressida_Robson@eisai.net /Ben_Speller@eisai.net. Tonic Life Communications: Alex Davies / DeepaPatel, +44-(0)7720-496-472 / +44-(0)7725-440-867, Alex.davies@toniclc.com /Deepa.Patel@toniclc.com.

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación